Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › sofosbuvir

sofosbuvir

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of sofosbuvir

36 trials tracked of sofosbuvir: 21 in phase 3 or 4 and 9 with published results. The most-cited published study has 302 citations.

36Trials tracked
21Phase 3 & 4
0Recruiting
9With published results
Phase distribution
Phase 4 4 Phase 3 17 Phase 2 14 Phase 1 1
  1. Phase 4 Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients Completed · 302 cited
  2. Phase 3 Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis Completed · 189 cited
  3. Phase 3 Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study Completed · 74 cited
  4. Phase 3 Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077) Completed · 54 cited
  5. Phase 3 A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection Completed · 40 cited
  6. Phase 3 Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection Completed · 31 cited
Show 30 more trials
  1. Phase 3 Efficacy and Safety of Sofosbuvir Plus Ribavirin in Adults With Chronic HCV Infection Completed · 30 cited
  2. Phase 4 Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis Completed · 27 cited
  3. Phase 3 Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Chronic Genotype 1 or 3 HCV Infection Completed · 18 cited
  4. Phase 4 SMV + SOF With/Without RBV for IFN-II Patients With CHC Completed
  5. Phase 4 The SIM-SOF Trial for Hepatitis C Completed
  6. Phase 3 Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis Completed
  7. Phase 3 Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis Completed
  8. Phase 3 Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C] Completed
  9. Phase 3 Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV Completed
  10. Phase 3 Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant Completed
  11. Phase 3 Efficacy and Safety of Sofosbuvir Plus Ribavirin in Japanese Adults With Chronic Genotype 2 HCV Infection Completed
  12. Phase 3 Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection Completed
  13. Phase 3 Phase 3 Study of Sofosbuvir and Ribavirin Completed
  14. Phase 3 A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection. Completed
  15. Phase 3 A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults Completed
  16. Phase 2 A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection Completed
  17. Phase 2 Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant Completed
  18. Phase 2 Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients Completed
  19. Phase 2 Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6 Completed
  20. Phase 2 Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816 Completed
  21. Phase 2 Efficacy and Safety of Grazoprevir (MK-5172), Elbasvir (MK-8742), and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074) Completed
  22. Phase 2 Combination Therapy for Chronic Hepatitis C Infection Completed
  23. Phase 2 Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant Completed
  24. Phase 2 Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients Completed
  25. Phase 2 An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease Completed
  26. Phase 2 Directly Observed Therapy for HCV in Chennai, India Completed
  27. Phase 2 Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083) Completed
  28. Phase 2 A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus Infection Completed
  29. Phase 2 Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study) Completed
  30. Phase 1 Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection Completed

Showing the 36 most-cited and recently-updated of 36 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Eight-Week Sofosbuvir-Velpatasvir Matches Twelve-Week Course in Non-Cirrhotic Hepatitis C
Gastroenterology RCT
Eight-Week Sofosbuvir-Velpatasvir Matches Twelve-Week Course in Non-Cirrhotic Hepatitis C Trial shows 8-week treatment works for Hepatitis C
In 880 treatment-naive adults with non-cirrhotic hepatitis C, 8 weeks of sofosbuvir-velpatasvir achieved SVR12 rates similar to the standard…
A shorter 8-week course of sofosbuvir and velpatasvir showed similar success rates to the standard 12-week treatment for Hepatitis C patient…
Oct 17, 2026
Machine learning models predict SVR in comorbid HCV patients treated with sofosbuvir, daclatasvir, and ribavirin in Pakistan
Primary Care & Family Medicine Cohort
Machine learning models predict SVR in comorbid HCV patients treated with sofosbuvir, daclatasvir, and ribavirin in Pakistan Can a computer predict your hepatitis C cure?
This retrospective cohort study evaluated machine learning prediction models in 221 comorbid HCV patients in Pakistan.
A new computer tool can spot which hepatitis C patients are likely to fail treatment before they even start taking pills.
Frontiers Apr 13, 2026